Cargando…

Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors

A series of new Olaparib derivatives was designed and synthesized, and their inhibitory activities against poly (ADP-ribose) polymerases-1 (PARP-1) enzyme and cancer cell line MDA-MB-436 in vitro were evaluated. The results showed that compound 5l exhibited the most potent inhibitory effects on PARP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Cheng-Zhi, Dong, Wei, Cui, Zhi-Wen, Yuan, Qiong, Hu, Xia-Min, Wu, Qing-Ming, Han, Xianlin, Xu, Yao, Min, Zhen-Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237161/ https://www.ncbi.nlm.nih.gov/pubmed/30427217 http://dx.doi.org/10.1080/14756366.2018.1530224

Ejemplares similares

Multifunctional Donepezil Analogues as Cholinesterase and BACE1 Inhibitors
por: Green, Keith D., et al.
Publicado: (2018)

Synthesis, pharmacology and molecular docking on multifunctional tacrine-ferulic acid hybrids as cholinesterase inhibitors against Alzheimer’s disease
por: Zhu, Jie, et al.
Publicado: (2018)

Arylaminopropanone Derivatives as Potential Cholinesterase Inhibitors: Synthesis, Docking Study and Biological Evaluation
por: Hudcová, Anna, et al.
Publicado: (2020)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors
por: Przybyłowska, Maja, et al.
Publicado: (2021)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2015)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

PET Imaging of PARP Expression Using (18)F-Olaparib
por: Wilson, Thomas C., et al.
Publicado: (2019)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
por: Park, Hye Jeong, et al.
Publicado: (2018)

Quinoline based furanones and their nitrogen analogues: Docking, synthesis and biological evaluation
por: Khokra, Sukhbir Lal, et al.
Publicado: (2016)

Sevanol and Its Analogues: Chemical Synthesis, Biological Effects and Molecular Docking
por: Belozerova, Olga A., et al.
Publicado: (2020)

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib()
por: Wang, Chen, et al.
Publicado: (2017)

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
por: Osoegawa, Atsushi, et al.
Publicado: (2017)

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2017)

Olaparib‐Based Photoaffinity Probes for PARP‐1 Detection in Living Cells
por: Voorneveld, Jim, et al.
Publicado: (2020)

PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
por: Liu, Chuan, et al.
Publicado: (2020)

Occurrence and preliminarily environmental risk assessment of selected pharmaceuticals in the urban rivers, China
por: Zhou, Haidong, et al.
Publicado: (2016)

Synthesis, Biological Evaluation and Docking Studies of Ring-Opened Analogues of Ipomoeassin F
por: O’Keefe, Sarah, et al.
Publicado: (2022)

Coumarin derivatives bearing benzoheterocycle moiety: synthesis, cholinesterase inhibitory, and docking simulation study
por: Hirbod, Kimia, et al.
Publicado: (2017)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation
por: Kageyama, Shun-ichiro, et al.
Publicado: (2020)

Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
por: Gross, Maya, et al.
Publicado: (2022)

Preliminarily Analysis of Carbamazepine (CBZ) C(0) in Patients Visited Isfahan Epileptic Clinics
por: Tolou-Ghamari, Zahra, et al.
Publicado: (2013)

Multipotent Cholinesterase Inhibitors for the Treatment of Alzheimer’s Disease: Synthesis, Biological Analysis and Molecular Docking Study of Benzimidazole-Based Thiazole Derivatives
por: Hussain, Rafaqat, et al.
Publicado: (2022)

Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer’s Disease
por: Hussein, Weiam, et al.
Publicado: (2018)

Novel phthalimide based analogues: design, synthesis, biological evaluation, and molecular docking studies
por: Othman, Ismail M. M., et al.
Publicado: (2019)

Molecular docking, synthesis and biological significance of pyrimidine analogues as prospective antimicrobial and antiproliferative agents
por: Kumar, Sanjiv, et al.
Publicado: (2019)

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
por: Daemen, Anneleen, et al.
Publicado: (2012)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
por: Qin, Hongyu, et al.
Publicado: (2023)

A simple method for the preparation of positive samples to preliminarily determine the quality of phosphorylation-specific antibody
por: Han, Yang, et al.
Publicado: (2022)

Prognostic Significance Of The Inflammatory Index-Based Scoring System In Patients Preliminarily Diagnosed With Multiple Myeloma In The Bortezomib-Based Chemotherapy Era
por: Liu, Siwei, et al.
Publicado: (2019)

Design and Synthesis of New Dual Binding Site Cholinesterase Inhibitors: in vitro Inhibition Studies with in silico Docking
por: Yar, Muhammad, et al.
Publicado: (2014)

Potential of Vitamin B6 Dioxime Analogues to Act as Cholinesterase Ligands
por: Gašo Sokač, Dajana, et al.
Publicado: (2022)

The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions
por: Orta, Manuel Luis, et al.
Publicado: (2014)

JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib
por: YANG, XUELI, et al.
Publicado: (2015)

PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
por: Yang, Xiao-Dong, et al.
Publicado: (2021)

PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells
por: Qin, Changjiang, et al.
Publicado: (2022)

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
por: Bonciarelli, Stefano, et al.
Publicado: (2023)

Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma
por: Jiang, Ruixin, et al.
Publicado: (2022)

Neuroactive Multifunctional Tacrine Congeners with Cholinesterase, Anti-Amyloid Aggregation and Neuroprotective Properties
por: Kozurkova, Maria, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_udl5f9117fb0dbaamvp6eafq5f